XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Identifiable Intangible Assets and Goodwill (Tables)
 9 Months Ended
Sep. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
September 29, 2024December 31, 2023
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$99,373 $(64,067)$35,306 $99,267 $(60,493)$38,773 
Brands(b)
1,749 (961)788 922 (877)45 
Licensing agreements and other2,720 (1,474)1,246 2,756 (1,458)1,297 
103,842 (66,502)37,340 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
— — 827 827 
IPR&D(c)
21,976 21,976 23,193 23,193 
Licensing agreements and other670 670 763 763 
22,646 22,646 24,784 24,784 
Identifiable intangible assets(d)
$126,488 $(66,502)$59,986 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by $385 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and impairments of $109 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Depo-Medrol.
(c)The decrease in the gross carrying amount reflects the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), $250 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and impairments of $240 million (see Note 4).
(d)The decrease is primarily due to amortization expense of $3.9 billion, measurement period adjustments related to our acquisition of Seagen of $625 million (see Note 2A) and impairments of $349 million (see Note 4).
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
September 29, 2024December 31, 2023
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$99,373 $(64,067)$35,306 $99,267 $(60,493)$38,773 
Brands(b)
1,749 (961)788 922 (877)45 
Licensing agreements and other2,720 (1,474)1,246 2,756 (1,458)1,297 
103,842 (66,502)37,340 102,944 (62,828)40,116 
Indefinite-lived intangible assets
Brands(b)
— — 827 827 
IPR&D(c)
21,976 21,976 23,193 23,193 
Licensing agreements and other670 670 763 763 
22,646 22,646 24,784 24,784 
Identifiable intangible assets(d)
$126,488 $(66,502)$59,986 $127,728 $(62,828)$64,900 
(a)The increase in the gross carrying amount includes the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), partially offset by $385 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and impairments of $109 million (see Note 4).
(b)The changes in the gross carrying amounts reflect the transfer of $827 million from indefinite-lived brands to finite-lived brands for Depo-Medrol.
(c)The decrease in the gross carrying amount reflects the transfer of IPR&D to developed technology rights of $727 million for talazoparib (Talzenna), $250 million of measurement period adjustments related to our acquisition of Seagen (see Note 2A) and impairments of $240 million (see Note 4).
(d)The decrease is primarily due to amortization expense of $3.9 billion, measurement period adjustments related to our acquisition of Seagen of $625 million (see Note 2A) and impairments of $349 million (see Note 4).
Schedule of Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2024
$67,783 
Additions(b)
661 
Impact of foreign exchange
125 
Balance, September 29, 2024
$68,570 
(a)All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 13A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.
(b)Additions represent measurement period adjustments related to our acquisition of Seagen (see Note 2A).